All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MDS Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.
As of January 1st, 2024, the MDS Hub will no longer be updated. Please continue to browse our archive for valuable content. For the latest updates in MDS, visit our sister site

Quality of life assessment and transfusion-free survival

Bookmark this article

During the MDS Hub Steering Committee meeting held on May 11, 2023, Theo de Witte chaired a discussion on quality of life (QoL) assessment and transfusion-free survival in patients with myelodysplastic syndromes (MDS), with contributions from Moshe Mittelman, Mikkael Sekeres, Rena Buckstein, and Yasushi Miyazaki.

Quality of life assessment and transfusion-free survival

de Witte discusses the impact of red blood cell transfusion dose density on progression-free survival in lower-risk MDS, then describes the novel patient-centric metric, time without transfusion reliance (TWiTR). He highlights the use of this metric in the P-2001 study, where TWiTR analysis demonstrated that transfusion independence is a critical endpoint for improving health-related QoL (HRQoL) in patients with higher-risk MDS. The committee discusses the association between acquired prolonged transfusion independence, and better survival and lack of disease progression. They also discuss the time period for transfusion independence assessment, endpoints for QoL studies, and the impact of frailty and disability on QoL in patients with MDS. They raise the need to repeat studies with TWiTR analysis and QoL assessment in large populations, and in patients with lower-risk MDS.


Subscribe to get the best content related to MDS delivered to your inbox